UCB
United States
87 articles about UCB
-
Huma and UCB partner to provide digital health solution to improve management of the rare disease, Myasthenia gravis
4/26/2023
Huma Therapeutics and UCB are partnering to offer a digital technology solution to help patients with the rare disease, Myasthenia gravis, better understand and manage their condition with the support of their clinician.
-
UCB Showcases Strength and Depth of Neurology Portfolio at 75th American Academy of Neurology (AAN) Annual Meeting
4/20/2023
UCB will showcase data from its expansive and innovative neurology portfolio at the 75th American Academy of Neurology (AAN) Annual Meeting, April 22-27, 2023.
-
UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance
4/17/2023
UCB (Euronext: UCB), a global biopharmaceutical company, today announced the U.S. Drug Enforcement Administration (DEA) has published a final rule stating that FINTEPLA oral solution is no longer subject to the Controlled Substances Act (CSA).
-
Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks
3/18/2023
UCB, a global biopharmaceutical company, announced detailed positive results from two Phase 3 studies evaluating the efficacy and safety of bimekizumab in the treatment of adults with moderate to severe hidradenitis suppurativa.
-
UCB to Present Eight Bimekizumab Abstracts at AAD 2023 with Results from Studies in Psoriasis, Psoriatic Arthritis, and Hidradenitis Suppurativa
3/16/2023
UCB, a global biopharmaceutical company, today announced that it will present eight bimekizumab abstracts across a range of IL-17 mediated diseases.
-
Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis
1/18/2023
UCB, a global biopharmaceutical company, today announced that Annals of the Rheumatic Diseases has published 24-week results from the Phase 3 BE MOBILE 1 and BE MOBILE 2 studies.
-
UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review
1/6/2023
UCB, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's filing to review a Biologic License Application (BLA) for its investigational treatment rozanolixizumab, and that the Agency has granted Priority Review.
-
Praxis Precision Medicines and UCB Announce Epilepsy Research Collaboration
12/13/2022
Praxis Precision Medicines, Inc. announced a strategic collaboration, based upon Praxis’ PRAX-020 program, for the discovery of small molecule therapeutics as potential treatments of KCNT1 related epilepsies.
-
UCB shared positive top-line results Friday from two Phase III studies of bimekizumab for adults with moderate to severe hidradenitis suppurativa.
-
UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa
12/9/2022
UCB, a global biopharmaceutical company, today announced positive top-line results from two Phase 3 studies, BE HEARD I and BE HEARD II, evaluating the efficacy and safety of bimekizumab in adults with moderate to severe hidradenitis suppurativa.
-
The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis
12/7/2022
UCB, a global biopharmaceutical company, today announced that The Lancet has published two articles detailing 24-week results from the Phase 3 BE OPTIMAL study and 16-week results from the Phase 3 BE COMPLETE study, evaluating the efficacy and safety of bimekizumab in the treatment of adults with active psoriatic arthritis.
-
UCB to present data at the American Epilepsy Society 76th Annual Meeting 2022 supporting a decades-long commitment to transforming epilepsy care
12/1/2022
UCB, a global biopharmaceutical company, today announced that data from its anti-seizure medication portfolio (brivaracetam, fenfluramine, lacosamide, and midazolam nasal spray) will be presented at the 76th American Epilepsy Society (AES) Annual Meeting (Nashville, Tennessee), December 2-6.
-
Epilepsia Publishes Interim Results of Open-Label Extension Study of FINTEPLA® (fenfluramine) Oral Solution in Patients with Lennox-Gastaut Syndrome (LGS)
11/23/2022
UCB today announced the publication of long-term open-label extension (OLE) study results of FINTEPLA® (fenfluramine) CIV in Epilepsia.
-
Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis
11/10/2022
UCB announced the first presentation of long-term, 52-week data from three Phase 3 studies evaluating the efficacy and safety of bimekizumab in adults with active psoriatic arthritis who were biologic-naïve, in adults with active non-radiographic axial spondyloarthritis, and in adults with active ankylosing spondylitis.
-
UCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022
11/8/2022
UCB, a global biopharmaceutical company, announced that it will present 15 abstracts across its rheumatology portfolio at ACR Convergence 2022 to be held in Philadelphia, November 10–14, 2022.
-
UCB U.S. HEADQUARTERS IN ATLANTA AWARDED PRESTIGIOUS LEED GOLD AND WELL PLATINUM CERTIFICATIONS
9/26/2022
UCB today announced that it has been awarded the prestigious LEED (Leadership in Energy and Environmental Design) Certification at the Gold level by the U.S. Green Building Council (USGBC) and WELL Certification at the Platinum level by the International WELL Building Institute.
-
UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting
9/22/2022
UCB announced today it is presenting results from across its portfolio in generalized myasthenia gravis (gMG) at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) annual meeting featuring the Myasthenia Gravis Foundation of America (MGFA) Scientific Session, September 21 – 24.
-
UCB Showcases Strength of the Expanding Dermatology Portfolio at the 31st EADV Congress
9/1/2022
UCB, a global biopharmaceutical company, announced that it will present 20 abstracts across its dermatology portfolio at the 31st European Academy of Dermatology and Venereology Congress in Milan, Italy, September 7-10.
-
UCB Partners in Health Economics and Outcomes Research to Evolve Solutions for Seizure Clusters
8/17/2022
UCB today announced three collaborations aimed at examining the impact of seizure clusters on patient and caregiver quality of life.
-
The rejection appears to be related to pre-approval inspection issues that need to be resolved before it can be approved.